Cancer Network
Spotlight
Acute Lymphoblastic LeukemiaAround the PracticeASCO Genitourinary Cancers SymposiumHER2-Positive Breast CancerNon-Small Cell Lung Cancer (NSCLC)Prostate Cancer
Clinical
View MoreBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
All NewsNP/PAPractice ManagementTechnology
Media
Around the PracticeClinical ConsultEnduring WebinarsExpert InterviewsK-CastMedical World NewsPodcastsReadout 360Tumor Board Series
Conferences
Publications
About Oncology JournalOncology Journal
Events
Live EventsVirtual Events
CME/CE
Resources
Image IQPollsQuizzesSlideshowsSponsoredToolkits
Subscribe
eNewsletterPrint Subscription

  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • Acute Lymphoblastic Leukemia
  • Around the Practice
  • ASCO Genitourinary Cancers Symposium
  • HER2-Positive Breast Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Prostate Cancer
ClinicalSee All >
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.

Surgical Debulking + Paclitaxel-Based Adjuvant Chemo Superior to Previous Ovarian Cancer Therapies

August 1, 1999
Oncology, ONCOLOGY Vol 13 No 8, Volume 13, Issue 8

Since its approval by the FDA in 1992, paclitaxel (Taxol) has been widely used in the treatment of ovarian cancer. Surgical debulking has also been proven to increase survival in women with this disease.

Since its approval by the FDA in 1992, paclitaxel (Taxol) has been widely used in the treatment of ovarian cancer. Surgical debulking has also been proven to increase survival in women with this disease.

A new study, presented at the 30th annual meeting of the Society of Gynecologic Oncologists, confirms that the use of both therapies has led to significant improvements in the survival rates of women with advanced-stage ovarian cancer. The investigators, Edward L. Trimble, MD, Michaele C. Christian, MD, and Carol Kosay, of the National Cancer Institute (NCI), perused the NCI Surveillance, Epidemiology and End Results (SEER) database and studied the medical histories of 2,194 women diagnosed with ovarian cancer between 1983 and 1987 and 2,082 women diagnosed between 1988 and 1994. They then compared the 5-year relative survival of women diagnosed during these two time periods for each International Federation of Gynecology and Obstetrics (FIGO) stage.

They found that the 5-year survival rates for women with stages III and IV ovarian cancer improved significantly between the two time periods studied (Table 1). The authors concluded that the current treatment modalities—surgical debulking and paclitaxel-based adjuvant chemotherapy—provide superior survival rates to older therapies.

Related Content:

Ovarian CancerONCOLOGY Vol 13 No 8
FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Cancer
FDA Grants Fast Track Designation to GEN-1 Immunotherapy for Treatment of Advanced Ovarian Cancer
Niraparib Maintenance Therapy Shows Promise for Chinese Patients With Platinum-Sensitive, Recurrent Ovarian Cancer
Niraparib Maintenance Therapy Shows Promise for Chinese Patients With Platinum-Sensitive, Recurrent Ovarian Cancer
Pooled Prevalence, Risk Factors of Chemotherapy-Related VTE in Ovarian Cancer Are Revealed
Pooled Prevalence, Risk Factors of Chemotherapy-Related VTE in Ovarian Cancer Are Revealed